Company intelligence / Profile preview

TBB

Schaffhausen, Switzerland

Ownership: Private
Employees: ~10
Development stage: Other

Overview

BB Biotech is a leading publicly listed investment company, focusing on high-growth biotech firms developing and commercializing novel therapies. Its portfolio comprises 20–35 companies, mostly in late-stage clinical development or commercial phase. Core holdings have achieved several key clinical and commercial milestones over 2024, supporting sector outperformance.

Therapeutic areas: ImmunologyMetabolic DisordersInfectious DiseasesCardiovascularOncologyNeurology
Modalities: Small moleculeMonoclonal antibodyGene therapyRNA therapyAntisense oligonucleotideCell therapy
Industry: Investors

Beyond the preview

Go deeper on TBB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBB.

Explore the full profile